Patient P-03395
Therapy response
Unstable
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
15%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S03
- Day 25 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 25.
Primary contributors, last 14 days
- Toxicity+12
- GI instability-11
- Inflammatory activity-7
- Nutritional resilience+5
- Treatment adherence+3
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Energy level
Daily log6/10
improving · +0.6 vs previous 14 d
Stress level
Daily log3.2/10
improving · -0.5 vs previous 14 d
Pessimism score
Daily log4.1/10
improving · -0.3 vs previous 14 d
Sleep quality
Wearable70.3/100
improving · +11.9 vs previous 14 d
Libido
Daily log4.6/10
improving · +0.6 vs previous 14 d
HRV
Wearable66.2 ms
stable · +2.4 vs previous 14 d
Toxicity
Blood18.5/100
stable · +0.0 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards restoration · 67 from the failing basin, 52 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -4 next day on high-intake days · n 18
Would not help
- AD-05 Adherence Supportonly 31% improved among 13 similar
- Keep lactose lowGI +3.3 next day on high-intake days · n 13
- Keep histamine lowGI +2.6 next day on high-intake days · n 23
- Keep caffeine lowGI +2.6 next day on high-intake days · n 18
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-4supporter · 95%
- Lactose+3.3detractor · 95%
- Histamine load+2.6detractor · 95%
- Caffeine+2.6detractor · 95%
- Alcohol+2.1detractor · 77%
- Dietary fat load-0.2no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Drug metabolism and exposure ↑40
- DNACYP2D6 poor metabolizer → higher exposure
- Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Inflammatory signalling ↓20
- MicrobiomeBacteroides fragilis expansion
- Autonomic recovery ↑20
- Wearable3,373 steps/day
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 2.8 · butyrate capacity 65/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 65 ms
- Sleep
- 8.1 h
- Steps
- 3,889
- Resting HR
- 69 bpm
Daily log: GI score 18, nutritional resilience 69, adherence 87.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.